GILD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GILD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gilead Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $19,330 Mil. Gilead Sciences's Total Assets for the quarter that ended in Dec. 2024 was $58,995 Mil. Therefore, Gilead Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.33.
The historical rank and industry rank for Gilead Sciences's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Gilead Sciences was 0.37. The lowest was 0.27. And the median was 0.33.
The historical data trend for Gilead Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
0.27 | 0.31 | 0.34 | 0.37 | 0.33 |
Gilead Sciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.37 | 0.31 | 0.34 | 0.34 | 0.33 |
For the Drug Manufacturers - General subindustry, Gilead Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Gilead Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Equity to Asset (A: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 19330 | / | 58995 | |
= | 0.33 |
Gilead Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Equity to Asset (Q: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 19330 | / | 58995 | |
= | 0.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (NAS:GILD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Gilead Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew D Dickinson | officer: EVP, Chief Financial Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Merdad Parsey | officer: Chief Medical Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Jeffrey Bluestone | director | C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858 |
Johanna Mercier | officer: Chief Commercial Officer | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Sandra Patterson | officer: SVP, Controllership | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Diane E. Wilfong | officer: SVP, Controller & CAO | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Deborah H Telman | officer: EVP, Corporate Affairs & GC | 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Brett A Pletcher | officer: EVP, Gen Counsel & Corp Sec | 333 LAKESIDE DRIVE, FOSTER CITY X1 94404 |
Anthony Welters | director | |
Javier Rodriguez | director | 601 HAWAII ST., EL SEGUNDO CA 90245 |
John Francis Cogan | director | 2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131 |
Gayle E Wilson | director | C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Olsen Per Wold | director | C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Sandra Horning | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Richard James Whitley | director | UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711 |
From GuruFocus
By GuruFocus News • 02-21-2025
By GuruFocus News • 02-11-2025
By GuruFocus News • 02-25-2025
By Business Wire • 02-11-2025
By GuruFocus News • 02-19-2025
By GuruFocus News • 02-20-2025
By GuruFocus News • 02-12-2025
By Business Wire • 02-18-2025
By GuruFocus News • 02-11-2025
By GuruFocus News • 01-28-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.